8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Suspended
Trial end date:
2021-12-17
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of 8-chloroadenosine and to see
how well it works in treating patients with acute myeloid leukemia that has returned after a
period of improvement (relapsed) or does not respond to treatment (refractory). Drugs used in
chemotherapy, such as 8-chloroadenosine, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading.